UNSPSC 51183611: Liraglutide

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 839I73S42A. European Medicines Agency schedules Liraglutide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25238. Liraglutide generally arises in the molecular formula C172H265N43O51.

The term LIRAGLUTIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, no. 2uy, 2003, list 49.) Most nations, for tariff and trade purposes, schedule liraglutide under HS 29371900 and SITC 54154. As of Q4 2014, LIRAGLUTIDE remains US FDA's Preferred Term for this commodity. Liraglutide bears US NLM identifiers UMLS ID C1456408 and NCI Concept Code C82239.

UNSPSC 51183611 Liraglutide is a Commodity code for a specific pharmaceutical product — in recent state and local activity, it appears tagged to multi-source generic pharmaceuticals procurement where individual drugs compete within broader therapeutic categories rather than being procured as standalone line items. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the issuing body actively soliciting under this code. Scope of work centers on pharmaceutical manufacturers supplying generic multi-source drugs and over-the-counter products to participating state and local government facilities across multiple states, including Oregon. Vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and support electronic data interchange (EDI) capabilities. Products require FDA compliance, expiration dates of at least one year from manufacture with minimum six-month shelf life, and detailed product specifications including National Drug Codes (NDC), SKUs, UPCs, strength, dosage form, trade names, packaging configurations, and manufacturing locations. Vendors must carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

MMCAP's RFP (Solicitation Number S1070000015802), posted January 20, 2026 with proposals due March 26, 2026, represents the primary recent activity under this code. The cooperative purchasing vehicle spans Minnesota and Oregon with potential for broader multi-state participation. Award evaluation weights pricing competitiveness at 75 percent, with fixed pricing (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract term runs two years for new vendors with optional extensions at MMCAP's discretion; incumbent vendors' amendments extend through June 30, 2028. All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. Vendors accept performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. The solicitation does not disclose specific award values or budget ranges and contains no identified set-aside designations.